Atrial fibrillation
Conditions
Interventions
Intervention group:Tongmai Yangxin Pills plus amiodarone
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Participants aged 18–75 years; diagnosed with persistent atrial fibrillation of the qi-and-yin deficiency pattern; duration of atrial fibrillation < 5 years; undergoing first-time radiofrequency catheter ablation; willing to participate in the study and having signed the informed consent form.
Exclusion criteria
Exclusion criteria: Valvular atrial fibrillation NYHA class IV or LVEF 50 mm Moderate-to-severe left ventricular hypertrophy (wall thickness > 1.5 cm) Patients with acute coronary syndrome or those requiring stent implantation History of cardiac surgery within the past 6 months or prior catheter ablation Duration of atrial fibrillation = 5 years Hyperthyroidism Atrial fibrillation associated with cardiomyopathy Bradyarrhythmia requiring pacemaker implantation Valvular atrial fibrillation; known bleeding tendency; presence of left atrial/left atrial appendage thrombus; or severe hemostatic/coagulation dysfunction Severe hepatic or renal insufficiency [ALT = 3 × ULN or eGFR < 45 mL/min/1.73 m²] Neurological or psychiatric disorders Allergy to any component of the study medication Pregnant or breastfeeding women Patients currently participating in other clinical studies Patients considered by the investigators to be unsuitable for participation in this study Contraindication to amiodarone use Concomitant use of other medications that may affect the results of the present study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| An episode of rapid atrial tachyarrhythmia lasting =30 seconds within 90 days after atrial fibrillation ablation; | — |
Secondary
| Measure | Time frame |
|---|---|
| The variation of atrial fibrillation burden;Time to first recurrence of atrial flutter/atrial fibrillation;Rate of electrical cardioversion;Changes in transthoracic echocardiography parameters;Rate of stroke and thromboembolic events;Short Form-36 Health Survey (SF-36) score, Atrial Fibrillation Effect on Quality-of-Life (AFEQT) score, and EHRA classification;Palpitation symptom score; | — |
Countries
China
Contacts
Public ContactHe Huang
Renmin Hospital of Wuhan University
Outcome results
None listed